2026年iCARDIO联盟心力衰竭全球实施指南。
完整摘要 · 中文译文
这是2026年更新的iCARDIO联盟心力衰竭全球实施指南版本，最初于2025年发布。在本指南中，我们旨在考虑医疗可及性方面的不一致、基础设施差异、资源限制以及多样化的地方实践，同时考虑限制现有指南全球适用性的实际问题和政治问题。我们需要能够应对全球患者和医疗服务提供者所面临独特挑战的普遍性建议。我们的iCARDIO联盟全球实施指南强调纳入新型疗法，同时将标准诊疗与最新证据相结合，以使临床医生能够优化患者照护。本文档涉及心力衰竭（HF），包括急性和慢性心力衰竭、射血分数降低的心力衰竭和射血分数保留的心力衰竭，以及射血分数改善的心力衰竭和心肌病。文档中突出了针对个体患者需求量身定制的情境特异性建议，对每种治疗的风险、获益和总体价值进行全面评估，旨在建立能够改善患者结局并减少这一易感人群住院负担的标准诊疗。本指南提供了基于证据的建议，代表了群体共识，同时参考了众多已发表指南中对本文所讨论许多问题的综述，但也在近期有新证据出现之处提出了新的建议。 整合。最重要的是，这些指南还就资源限制可能对心力衰竭患者护理造成制约的诸多问题提供了建议。此类“经济调整”建议旨在为“资源较为有限”或“资源严重受限”的情况下提供指导。因此，本文件不仅提供了一套全面且简洁的建议，以指导心力衰竭管理的各个方面，并针对这一重大全球健康挑战的药理学、非药理学、侵入性及介入性管理制定统一策略，适用于全球各地的医疗保健需求。这是iCARDIO联盟《全球心力衰竭实施指南》2026年更新版——该指南最初于2025年发布。在本指南中，我们旨在考虑医疗服务的可及性差异、基础设施差异、资源限制以及各地不同的临床实践，同时兼顾限制现有指南全球适用性的实际及政策问题。我们有必要制定普遍适用的建议，以应对全球患者和医疗提供者所面临的独特挑战。我们的iCARDIO联盟《全球心力衰竭实施指南》强调纳入新型疗法，同时将标准治疗与最新证据相结合，使临床医生能够优化患者护理。本文件涉及心力衰竭（HF），包括急性和慢性心力衰竭、射血分数降低的心力衰竭以及心力衰竭。 射血分数保留的心力衰竭，以及射血分数改善的心力衰竭和心肌病。针对个体患者需求量身定制的情境特异性建议被重点强调，提供了对每种治疗的风险、获益和整体价值的全面评估，旨在建立一种护理标准，以改善患者结局并减轻这一易感人群的住院负担。这些指南提供了基于证据的建议，代表了考虑到此处讨论的许多问题已在其他众多已发表指南中回顾过的专家组共识，但同时也针对近期出现的新证据提出了新建议。最重要的是，这些指南还对资源限制可能对心衰患者所获护理造成约束的若干问题提供了建议。此类“经济调整”建议旨在为“资源较为有限”或“资源严重有限”的情况提供指导。因此，本文件不仅提供了一套全面且简明的建议，以指导心衰管理的各个方面，还以统一的策略涵盖了这一重大全球健康挑战的药物、非药物、侵入性和介入性管理，适用于全球各地的医疗需求。这是iCARDIO联盟全球心力衰竭实施指南的2026年更新版——最初于2025年发布。在这些指南中，我们旨在考虑医疗可及性方面的不一致性，同时考虑各 ying基础设施、资源限制和多样化的本地实践，以及限制当前可用指南全球适用性的实际和政治问题。需要能够应对全球患者和医疗保健提供者所面临独特挑战的通用建议。我们的iCARDIO Alliance全球实施指南强调纳入新疗法，同时将标准治疗与最新证据相结合，使临床医生能够优化患者护理。本文件关于心力衰竭（HF），包括急性和慢性心力衰竭、射血分数降低的心力衰竭和射血分数保留的心力衰竭，以及射血分数改善的心力衰竭和心肌病。突出了针对个体患者需求定制的特定情境建议，提供对每种治疗的风险、获益和总体价值的全面评估，旨在建立一种标准治疗，以改善患者结局并减少这一易感人群的住院负担。这些指南提供了循证建议，代表了小组共识，考虑了许多其他已发表指南，这些指南已审查了本文讨论的许多问题，但也在最近出现新证据的情况下提出了新建议。最重要的是，这些指南还就若干问题提供了建议，在这些问题中，资源限制可能对HF患者所接受的护理造成约束。此类“经济调整”建议 旨在为“资源有限”或“资源严重受限”的情况提供指导。因此，本文件不仅提供了一套全面且简明的建议，以指导心力衰竭管理的各个方面，还包含针对这一重大全球健康挑战的药物、非药物、有创及介入治疗管理的统一策略，该策略适用于全球范围内的医疗需求。
完整摘要 · 英文原文
This is the updated 2026 version of the iCARDIO Alliance Global Implementation Guidelines on Heart Failure - originally published in 2025. In these guidelines, we aim to consider inconsistencies in healthcare access, varying infrastructure, re-source constraints and diverse local practices as well as practical and political issues that restrict the global applicability of currently available guidelines. There is a need for universal recommendations that address the unique challenges faced by patients and healthcare providers worldwide. Our iCARDIO Alliance Global Implementation Guidelines emphasize the in-corporation of novel therapies, while integrating standard of care with the most up-to-date evidence to enable clinicians to optimize patient care. This document is about heart failure (HF), including acute and chronic heart failure, heart failure with reduced ejection fraction and heart failure with preserved ejection fraction as well as HF with improved ejection frac-tion and cardiomyopathies. Context-specific recommendations tailored to individual patient needs are highlighted providing a thorough evaluation of the risks, benefits, and overall value of each therapy, aiming to establish a standard of care that im- proves patient outcomes and reduces the burden of hospitalization in this susceptible population. These guidelines provide evidence-based recommendations that represent a group consensus considering the many other published guide-lines that have reviewed many of the issues discussed here, but they also make new recommendations where new evidence has recently emerged. Most importantly these guidelines also provide recommendations on a number of issues where re-source limitations may put constraints on the care provided to HF patients. Such "economic adjustment" recommendations aim to provide guidance for situations when "Resources are somewhat limited" or when "Resources are severely limited". Hence, this document presents not only a comprehensive but also concise set of recommendations to guide all aspects of HF management with a unified strategy for the pharmacological, non-pharmacological, invasive and interventional man-agement of this significant global health challenge that is applicable to the needs of healthcare around the globe. This is the updated 2026 version of the iCARDIO Alliance Global Implementation Guidelines on Heart Failure - originally published in 2025. In these guidelines, we aim to consider inconsistencies in healthcare access, varying infrastructure, re-source constraints and diverse local practices as well as practical and political issues that restrict the global applicability of currently available guidelines. There is a need for universal recommendations that address the unique challenges faced by patients and healthcare providers worldwide. Our iCARDIO Alliance Global Implementation Guidelines emphasize the in-corporation of novel therapies, while integrating standard of care with the most up-to-date evidence to enable clinicians to optimize patient care. This document is about heart failure (HF), including acute and chronic heart failure, heart failure with reduced ejection fraction and heart failure with preserved ejection fraction as well as HF with improved ejection frac-tion and cardiomyopathies. Context-specific recommendations tailored to individual patient needs are highlighted providing a thorough evaluation of the risks, benefits, and overall value of each therapy, aiming to establish a standard of care that im- proves patient outcomes and reduces the burden of hospitalization in this susceptible population. These guidelines provide evidence-based recommendations that represent a group consensus considering the many other published guide-lines that have reviewed many of the issues discussed here, but they also make new recommendations where new evidence has recently emerged. Most importantly these guidelines also provide recommendations on a number of issues where re-source limitations may put constraints on the care provided to HF patients. Such "economic adjustment" recommendations aim to provide guidance for situations when "Resources are somewhat limited" or when "Resources are severely limited". Hence, this document presents not only a comprehensive but also concise set of recommendations to guide all aspects of HF management with a unified strategy for the pharmacological, non-pharmacological, invasive and interventional man-agement of this significant global health challenge that is applicable to the needs of healthcare around the globe. This is the updated 2026 version of the iCARDIO Alliance Global Implementation Guidelines on Heart Failure - originally published in 2025. In these guidelines, we aim to consider inconsistencies in healthcare access, varying infrastructure, re-source constraints and diverse local practices as well as practical and political issues that restrict the global applicability of currently available guidelines. There is a need for universal recommendations that address the unique challenges faced by patients and healthcare providers worldwide. Our iCARDIO Alliance Global Implementation Guidelines emphasize the in-corporation of novel therapies, while integrating standard of care with the most up-to-date evidence to enable clinicians to optimize patient care. This document is about heart failure (HF), including acute and chronic heart failure, heart failure with reduced ejection fraction and heart failure with preserved ejection fraction as well as HF with improved ejection frac-tion and cardiomyopathies. Context-specific recommendations tailored to individual patient needs are highlighted providing a thorough evaluation of the risks, benefits, and overall value of each therapy, aiming to establish a standard of care that im- proves patient outcomes and reduces the burden of hospitalization in this susceptible population. These guidelines provide evidence-based recommendations that represent a group consensus considering the many other published guide-lines that have reviewed many of the issues discussed here, but they also make new recommendations where new evidence has recently emerged. Most importantly these guidelines also provide recommendations on a number of issues where re-source limitations may put constraints on the care provided to HF patients. Such "economic adjustment" recommendations aim to provide guidance for situations when "Resources are somewhat limited" or when "Resources are severely limited". Hence, this document presents not only a comprehensive but also concise set of recommendations to guide all aspects of HF management with a unified strategy for the pharmacological, non-pharmacological, invasive and interventional man-agement of this significant global health challenge that is applicable to the needs of healthcare around the globe.